Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers ...Middle East

Astellas' GLOW trial, the second Phase 3 trial in CLDN18.2 positive, HER2-negative locally advanced unresectable or metastatic gastric and GEJ cancers, meets primary endpoint for progression-free survival (PFS) and key secondary endpoint for overall survival (OS) GLOW results, along with...

Hence then, the article about astellas announces zolbetuximab meets primary endpoint in phase 3 glow trial as first line treatment in claudin 18 2 positive her2 negative locally advanced unresectable or metastatic gastric and gastroesophageal junction gej cancers was published today ( Friday 16/12/2022 - 03:00 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers )

Also on site :

• Europe’s cyber agency blames hacking gangs for massive data breach and leak
• AI companies are building huge natural gas plants to power data centers. What could go wrong?
• The Trump Dictatorship Is Cracking Up